No patients in the trial experienced severe adverse events related to the treatment. The mean Bullous Pemphigoid Disease Area Index (BPDAI) decreased from 32 on day 1 to 19.6 on day 42.

Key takeaways: Patients with bullous pemphigoid treated with IL-2 had fewer days to disease control vs. those on corticosteroids alone. In the first 2 weeks of IL-2 treatment, a significant ...

Bullous pemphigoid (BP) is a condition that affects the skin with an autoimmune etiology. ... Treatment aims to make the disease tolerable by decreasing the rate at which bullae form.

Like many autoimmune diseases, bullous pemphigoid can get better and worse over time; it can go into remission (no symptoms), and it can relapse (flare up). A blood test (BP 180 antibody ...

DEAR DR. ROACH: My 94-year-old father was diagnosed with bullous pemphigoid. He lives in a senior living facility. The nursing assistants were initially reluctant to help him treat the condition ...

Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-fil… ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.. Bullous pemphigoid is a chronic, relapsing skin disease ...

Kawaguchi Y, Shimauchi R, Nishibori N et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus cases [published ...

Bone Marrow Transplantation - Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Skip to main content.